Brevan Howard Capital Management
LRMR icon

Brevan Howard Capital Management’s Larimar Therapeutics LRMR Stock Holding History

Brevan Howard Capital Management’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$59.5K Buy
+19,504
New +$77.4K ﹤0.01% 2011
2025
Q2 		– Sell
-31,880
Closed -$68.5K – 1935
2025
Q1 		$68.5K Buy
+31,880
New +$101K ﹤0.01% 1075

Other funds holding LRMR

Deerfield Management
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Driehaus Capital Management
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Brevan Howard Capital Management's LRMR Position: Q2 2026 in Review

Brevan Howard Capital Management opened a new position in Larimar Therapeutics (LRMR) in Q2 2026: 19,504 shares worth $59.5K. The stake represents ﹤0.01% of the portfolio and ranks #2011 among its holdings. This is a return to the name: Brevan Howard Capital Management previously reported a position in LRMR as recently as Q1 2025.

Brevan Howard Capital Management first reported a position in LRMR in Q1 2025 and has held it in 2 quarters since. The position peaked at $68.5K in Q1 2025. 163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • Brevan Howard Capital Management held 19,504 shares of Larimar Therapeutics worth $59.5K as of Q2 2026.
  • Larimar Therapeutics was a new Brevan Howard Capital Management position in Q2 2026.
  • Larimar Therapeutics made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #2011 holding.
  • Brevan Howard Capital Management first reported a position in Larimar Therapeutics in Q1 2025 and has held it in 2 quarters since.
  • Brevan Howard Capital Management's Larimar Therapeutics position peaked at $68.5K in Q1 2025.
  • 163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.